Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2024 Earnings Call Transcript August 8, 2024Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Posts Tagged ‘NASDAQ:ARWR’
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.01634 EPS, expectations were $-0.06. Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.03 EPS, expectations were $-0.78.
5 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 5 most promising biotech stocks to buy according to analysts.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
5 Biotech Stocks with Biggest Upside
In this article, we discuss 5 biotech stocks with biggest upside.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?
Baron Funds, an investment management company, released its “Baron Opportunity Fund” first quarter 2023 investor letter. A copy of the same can be downloaded here.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
12 High Growth Healthcare Stocks to Buy
The healthcare sector proved its mettle in 2022.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2022 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode.
Baron Funds Sold Arrowhead Pharmaceuticals (ARWR) to Reallocate to Higher Conviction Ideas
Baron Funds, an asset management company, released its “Baron Global Advantage Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
Baron Funds: “We Retain Conviction in Arrowhead (ARWR)”
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2022 investor letter – a copy of which can be downloaded here.
Top 5 Stock Picks of Frank Fu’s CaaS Capital
In this article, we discuss the top 5 stock picks of Frank Fu's CaaS Capital.
Should I Avoid Arrowhead Pharmaceuticals Inc. (ARWR)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end...
Is it a Good Thing to Keep Your Arrowhead Pharmaceuticals (ARWR) Shares?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” third quarter 2021 investor letter – a copy of which can be ...
Is Arrowhead Pharmaceuticals (ARWR) Still a Great Investment Pick?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Funds Are Piling Into Arrowhead Pharmaceuticals Inc. (ARWR)
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money ...
Is Arrowhead Pharmaceuticals (ARWR) A Good Stock To Buy Now?
Baron Opportunity Fund recently published its second-quarter commentary – a copy of which can be downloaded here.
Here is What Hedge Funds Think About Arrowhead Pharmaceuticals Inc. (ARWR)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Opportunity Fund” first quarter 2021 investor letter – a copy of which can be downloaded here.
Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here.
Is ARWR Stock A Buy or Sell?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Is Arrowhead Pharmaceuticals (ARWR) Stock a Buy For 2021?
Baron Health Care Fund recently published its fourth-quarter commentary – a copy of which can be downloaded here.
Is ARWR A Good Stock To Buy Now According To Hedge Funds?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity...
Hedge Fund and Insider Trading News: Mike Novogratz, Crispin Odey, Steve Cohen, Fulcrum Asset Management, Elliott Management, Envestnet Inc (ENV), Arrowhead Pharmaceuticals Inc (ARWR), and More
Bitcoin is like "digital gold" and won't be used in the same way as traditional currency for at least the next five years, billionaire investor Mike Novogratz told Bloomberg on...
Hedge Fund and Insider Trading News: Ray Dalio, Balyasny Asset Management, Asia Research and Capital Management, Alcur Select, Lam Research Corporation (LRCX), Enghouse Systems Limited (EGHSF), and More
Bridgewater Associates founder Ray Dalio is giving $50 million to NewYork-Presbyterian to fight health inequality at a time when the coronavirus pandemic has laid bare the disproportionate...
Arrowhead Pharmaceuticals Inc. (ARWR) Fell Out Of Favor With Hedge Funds
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Did Hedge Funds Make The Right Call On Arrowhead Pharmaceuticals Inc. (ARWR) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Is Arrowhead Pharmaceuticals Inc. (ARWR) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
Coronavirus is probably the #1 concern in investors' minds right now. It should be.
Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money ...
Hedge Funds Have Never Been More Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
Is Arrowhead Pharmaceuticals, Inc.
Hedge Fund and Insider Trading News: Ken Griffin, Tom Steyer, Amber Capital, Acadia Pharmaceuticals Inc. (ACAD), and More
PARIS (Reuters) - Activist shareholder Amber Capital, which is being sued by Lagardere (LAGA.PA), said on Monday the lawsuit was baseless and it would continue to seek strategy...
Is Arrowhead Pharmaceuticals Inc (ARWR)’s Recently Published U.S. Patent Application A Blockbuster?
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) business model of going after extrahepatic targets and establishing first mover advantage has the potential to be amplified by gaining...
Hedge Funds Have Never Been This Bullish On Arrowhead Pharmaceuticals, Inc. (ARWR)
A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as...
Here’s What Hedge Funds Think About Arrowhead Pharmaceuticals, Inc. (ARWR)
Is Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR): Hedge Funds Are Snapping Up
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers...
Hedge Fund and Insider Trading News: Marc Lasry, Elliott Management, Third Point LLC, StealthGas Inc. (GASS), Pivotal Software Inc (PVTL), and More
Who knows what’s moving markets? Marc Lasry says he knows. It’s politics, and concern the Democrats will triumph in next week’s midterms.
Here is What Hedge Funds Think About Arrowhead Pharmaceuticals Inc (ARWR)
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
Arrowhead Pharmaceuticals Inc (ARWR): Any Good Hearted Billionaires Out There (Willing To Pick Up Where Arrowhead Left Off)?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) just shocked markets with the announcement that it would be discontinuing its lead development programs.
Today’s Movers And Shakers In Biotech: Arrowhead Pharmaceuticals Inc (ARWR) And Kite Pharma Inc (KITE)
We’re closing in on the end of the week, and it’s time to take a look at which of the companies in the biotech space have moved the most, and what’s driving the action behind...
The Chairmen of 4 Companies Unload Shares, Plus Insider Buying at Lions Gate (LGF)
The markets are in the green this morning, buoyed by existing home sales rising by 3.2% in September. On the other hand, weekly jobless claims in the U.S.
Arrowhead Pharmaceuticals Inc. (ARWR), Spring Bank Pharmaceuticals, Inc. (SBPH) Collaborate On HBV
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) and Spring Bank Pharmaceuticals, Inc.
Why JPMorgan (JPM), Facebook (FB), and Fitbit (FIT) Are Among Today’s Trending Stocks
Despite declining oil and gold prices, the markets are up on Wednesday, driven by surprisingly positive Chinese international trade data and a stronger dollar.
See Which of These Two Surging Biotech Stocks Hedge Funds Approve On
Thursday turns out a bad day for investors as major indices slipped by more than 1% amid pressure from declining global markets and hours before Fed Chair Janet Yellen speech...
One Dipping Stock Hedge Funds Like and a Healthcare Company Smart Money is Not Bullish On
As the markets started the end of the week on a negative note, amid almost unchanged wholesale prices and in the anticipation of the next week's Fed meeting.
Arrowhead Research Corp (ARWR): Bridger Management Builds 5.5% Passive Stake
Roberto Mignone’s Bridger Management has amassed a 5.5% stake in Arrowhead Research Corp (NASDAQ:ARWR) according to a 13G filing with the Securities and Exchange Commission ...
